초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 09월 23일 17시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제126회 대한화학회 학술발표회 및 총회 Multiplexed, scalable gene editing platform for modeling cancer and identifying effective cancer therapy

2020년 9월 18일 19시 56분 26초
LIFE2-3 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
화 13시 : 50분
Life Chemistry - Recent Progress in Life Chemistry
저자 및
Tackhoon Kim
Chemical Kinomics Research Center, Korea Institute of Science and Technology, Korea
Cancer is rarely a monogenic disease. Nor is cancer therapy feasible with targeting single oncogene. There is an urgent need for platforms that enable multiplexed gene editing to account for complex genetic alterations in cancer, and also to identify drug targets which synergize when targeted together. Here I discuss two breakthroughs that enable CRISPR-Cas9 based genetic engineering and screening platforms. First part of the talk will introduce combinatorial CRISPR screens that identified novel combination of tyrosine kinase inhibitors that synergize for treating triple negative breast cancer (TNBC). FYN tyrosine kinase was identified as an adjuvant target whose inhibition can synergistically treat TNBC both in vitro and in vivo with wide range of tyrosine kinase inhibitors such as IGF1R, EGFR and ABL inhibitors. The second part of the talk will introduce novel gene circuit that enables multiplexed, sequential gene expression platform that can be used as the next generation tumorigenesis model by the accumulation of mutations over time. This gene circuit was successfully implemented to sequentially introduce indel mutation at key tumor suppressor genes at any desired time point. These highly innovative genetic engineering and screening platforms will potentially revolutionize current practices in cancer research and cancer therapeutics.